Neurofibromatosis type 1-related tumours in paediatrics: an evolving treatment landscape

Lancet Child Adolesc Health. 2020 Jul;4(7):488-490. doi: 10.1016/S2352-4642(20)30169-3.

Authors

Amy E Armstrong¹, Nicole M Brossier², Angela C Hirbe³

Affiliations

¹ Division of Hematology and Oncology, Department of Pediatrics, Washington University School of Medicine, St. Louis, MO 63110, USA. Electronic address: armstrongae@wustl.edu.
² Division of Hematology and Oncology, Department of Pediatrics, Washington University School of Medicine, St. Louis, MO 63110, USA.
³ Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.

PMID: 32562630
DOI: 10.1016/S2352-4642(20)30169-3

No abstract available

MeSH terms

Benzimidazoles / therapeutic use
Child
Glioma / drug therapy
Humans
Imatinib Mesylate / therapeutic use
Mitogen-Activated Protein Kinases / antagonists & inhibitors
Nerve Sheath Neoplasms / drug therapy
Neurofibroma, Plexiform / genetics
Neurofibroma, Plexiform / therapy
Neurofibromatosis 1 / genetics
Neurofibromatosis 1 / therapy*
Neurofibromin 1 / genetics
Protein Kinase Inhibitors / therapeutic use

Substances

AZD 6244
Benzimidazoles
NF1 protein, human
Neurofibromin 1
Protein Kinase Inhibitors
Imatinib Mesylate
Mitogen-Activated Protein Kinases

Associated data

ClinicalTrials.gov/NCT02101736